FT. LAUDERDALE, Fla. -- (BUSINESS WIRE) -- Puget Technologies (OTCBB: PUGE) is pleased to inform shareholders and the general public that its new subsidiary, Cannabis Biotech, is launching the development research of three new projects. Headed up by prominent international medical marijuana authority Kenneth Morrow, Cannabis Biotech’s research will focus on the growing number of patients who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.
President and CEO of Puget Technologies Ron Leyland said, “These research projects will showcase our value and our commitment to the industry.” He added, “We look forward to expanding the body of empirical data supporting the legitimacy of cannabis as an important tool in easing suffering and reducing symptoms associated with many serious ailments.”
According to a recent Pew Research report, for the first time in more than 40 years a majority of Americans favor legalization of marijuana use. Currently 20 U.S. states and the District of Columbia have enacted laws to legalize the use of medical marijuana.
CNN Chief Medical Correspondent Dr. Sanjay Gupta recently made global headlines when he changed his mind about cannabis, saying science backs the use of medical marijuana. According to an article based on Gupta’s recent documentary, “WEED,” there are several medical conditions for which patients can use cannabis – cancer, glaucoma, HIV/AIDS, muscle spasms, seizures, severe pain, severe nausea, dramatic weight loss and muscle atrophy.
More information about Cannabis Biotech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.